Summary
Background Coronavirus disease 2019 (COVID-19) is an acute respiratory illness characterised by a range of symptoms. Severe cases of COVID-19 could lead to hospitalisation and intensive care unit admission. However, little is known about the symptomatic experience of outpatients with COVID-19, or its daily life impact; the objective of this qualitative research was to document this experience.
Methods Thirty US adult patients with COVID-19 were interviewed within 21 days of diagnosis. To be included, patients had to self-report one of the following: fever, cough, shortness of breath/difficulty breathing, change/loss of taste/smell, vomiting/diarrhoea or body/muscle aches. Patients were asked open-ended questions to elicit their symptoms and the impacts COVID-19 had on their daily lives. Interviews were transcribed and inductively coded to perform thematic analysis and propose a conceptual model. The adequacy of the sample size was assessed by conceptual saturation analysis. Five independent clinicians were also interviewed about their experience treating outpatients with COVID-19.
Findings Patient-reported concepts were organised into six symptom themes (upper respiratory, lower respiratory, systemic, gastrointestinal, smell and taste, and other) and seven impact themes (activities of daily living, broad daily activities, leisure/social activities, physical impacts, emotional impacts, professional impacts and quarantine-specific impacts). Symptom type, severity, duration and time of onset varied greatly by patient. Clinicians endorsed all symptoms reported by patients.
Interpretation The manifestation of symptoms in outpatient COVID-19 is heterogeneous and affects all aspects of daily life. While reported symptoms were in line with previously published reports, patients offered new detailed insights into their symptomatic experiences and the impacts that symptoms had on their daily lives. Future studies should explore the symptoms and impacts of COVID-19 longitudinally, to better understand their early onset, their progression/resolution and the possible long-term implications of COVID-19.
Funding This research was sponsored and paid for by Regeneron Pharmaceuticals, Inc.
Evidence before this study Databases used: PubMed. Criteria for inclusion: qualitative study of the outpatient experience of COVID-19 (December 2019 – March 2021). Search terms included “qualitative” OR “interviews” AND “COVID-19” or “coronavirus”. The quality of the evidence was deemed not relevant to the current study, as the work was related to other contexts (eg, hospitalized patients or treatment of COVID-19), or data was collected quantitively (ie, questionnaire/survey) and did not include an in-depth perspective of the outpatient experience.
Added value of this study This research fills important gaps in the literature, as the outpatient experience (ie, symptoms and daily life impacts) of COVID-19 has not been documented qualitatively.
Implications of all the available evidence Findings of this research may be used to supplement existing knowledge of the outpatient experience of mild-to-moderate COVID-19, to further inform treatment guidelines. This work also provides an evidence base for identifying the symptoms and impacts important for evaluating potential treatment benefit in outpatients.
Competing Interest Statement
DR is a Regeneron Pharmaceuticals, Inc. employee/stockholder and former Roche employee and current stockholder. SS and VM are Regeneron Pharmaceuticals, Inc. employees/stockholders. AP has received consulting fees from Regeneron Pharmaceuticals, Inc., honoraria from NACE (CME) and has participated in an advisory board for Boehringer Ingelheim. NM, AR, and KP are employees of Modus Outcomes. PM is the co-founder and CEO of Modus Outcomes. NM, AR, KP, and PM consulted for Regeneron Pharmaceuticals, Inc.
Funding Statement
This study was funded by Regeneron Pharmaceuticals, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study documents, including the protocol, demographic and health information form, interview guide, screener and informed consent form, received ethical approval from the New England Independent Review Board (study number: 1291666) prior to any contact with patients.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos